Correction to: Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways

Gastric Cancer. 2020 Jan;23(1):116-117. doi: 10.1007/s10120-019-01013-y.

Hiroshi Moro^{1

2}, Naoko Hattori¹, Yoshiaki Nakamura^{1

3}, Kana Kimura¹, Toshio Imai⁴, Masahiro Maeda¹, Masakazu Yashiro⁵, Toshikazu Ushijima^{6

7}

¹ Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
² Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.
³ Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
⁴ Central Animal Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
⁵ Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
⁶ Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan. tushijim@ncc.go.jp.
⁷ Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan. tushijim@ncc.go.jp.

Abstract

Recently published the priming.